In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|August 20, 2021
BMS Elects to In-License AI-Designed, Immune-Modulating Drug Candidate from Exscientia
Author(s)BioPharm International Editors
Bristol Myers Squibb has exercised the option to in-license an immune-modulating drug candidate developed by Exscientia.
Advertisement
According to an Aug. 18, 2021 press release from artificial intelligence (AI)-driven pharmatech company Exscientia, Bristol Myers Squibb (BMS) has exercised the option to in-license an immune-modulating drug candidate that Exscientia developed.
The companies are already involved together in two active collaborative projects, focusing on multiple therapeutic areas. For this latest collaboration, the in-licensed candidate targets a critical immunological kinase that has proven difficult to target previously. In designing a novel candidate that overcame the targeting challenges associated with the immunological kinase, Exscientia employed its end-to-end platform to drive the discovery process.
“We are focused on using our patient-first AI technology to design precision engineered drugs against challenging drug product profiles. We are seeing great efficiency from our platform,” said Andrew Hopkins, CEO of Exscientia, in the press release. “This drug candidate molecule was just the 150th novel compound to be designed and tested and it was identified within 11 months of starting drug design. In partnership with Bristol Myers Squibb and its world-class research, clinical, and commercialization capabilities, we look forward to advancing this candidate into the next stage of development.”
“We are pleased to in-license our first drug candidate resulting from our strategic collaboration with Exscientia. AI and machine learning continue to play important roles in drug discovery and Exscientia has delivered a promising development candidate in the field of immunology. We look forward to our continued collaboration and further advancing this candidate for the potential benefit of patients with unmet medical need,” Rupert Vessey, president of Research & Early Development at BMS, added in the press release,
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5